Human ovarian cancer cell line with acquired olaparib resistance, harboring BRCA2 secondary mutation
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.